Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated coverage of the stock with a ‘Buy’ rating and a $72 price target. The research ...

Zai Lab Limited (NASDAQ:ZLAB) is one of the 10 biotech stocks screaming a buy. On June 17, the company delivered positive ...

Investing.com -- Lipella Pharmaceuticals Inc (OTC: LIPO) stock plunged 23% after the clinical-stage biotechnology company was delisted from the Nasdaq Capital Market due to rule violations related to ...

The Company was notified by the Hearings Panel of its determination to delist the Company's common stock effective today.

Alexandria Real Estate Equities, Inc.'s fundamentals remain strong with a 7.4% yield, steady demand, and confident management ...

Parataxis is launching a Bitcoin treasury platform for South Korean institutional investors, which saw Bridge Bio’s stock ...

However, RBC Capital has reiterated that Vertex could require stronger execution to adopt Alyftrek to justify the current ...

Zealand Pharma A/S’s shares have slid to a near 18-month low, as the Danish biotech’s experimental weight-loss drug faces mounting competition and a long wait ahead for crucial trial results.

In 10 years, there will probably be a different set of trending topics on The Street, but those changes won't stop the market ...

The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given ...

Caris's stock (CAI) opened at $27 a share, or 28.6% above the IPO price of $21 a share. Shares climbed to an intraday high of $29.40 soon after the open, before paring some gains but still up 27.1% in ...

On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the agency unveiled a pilot ...